Factsheet 2020

We develop early clinical assets to advance into the clinic with pharmaceutical partners

unlocking novel therapeutics
eleva

Eleva is opening a realm of unprecedented therapies by harnessing an inconspicuous but incredibly efficient partner: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they downright invite easy, stable engineering and reliable output. We have harnessed its outstanding features to create drug candidates and take them to clinical stages, ready for a bright future.

Business model

We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities. Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.

	RESEARCH	PRECLINICAL	PHASE I	PHASE II
Indication	**Therapies for complement disorders**			
C3 glomerulopathy (C3G)	Compleva FH/CPV-101 (natural complement regulator)			
Complement disorders	Compleva MFHR1/CPV-102 (novel multi-level complement regulator)			
Complement disorders	Compleva FHL/CPV-103 (natural complement regulator)			
	Enzyme replacement therapies			
Fabry disease	Repleva AGAL/RPV-001 (glyco-improved Fabry-ERT)			
Pompe disease	Repleva GAA/RPV-002 (glyco-improved Pompe-ERT)			

Key characteristics of BryoTechnology at one glance

- Outstanding product quality, especially regarding posttranslational modifications
- Batch-to-batch stability
- Excellent safety profile
- Virus- and TSE-free production in customizable strains, e. g. for glycoengineering and antibody drug conjugates

BryoTechnology

Everything you expect from cell line development – yet without the problems



Tailored glycosylation

Wherever glycosylation is a problem, moss is your solution. Moss has no core α-1,6 fucose to begin with. Any other glycans can be modified to the desired effect, be it by knocking certain genes out or inserting the necessary transferases. No allergens, more power. We are experts in moss glycodesign, “humanizing” the molecules’ glycostructure. We have demonstrated excellent organ uptake, even in clinical studies. Our “glyco platform” is just what you were hoping for.

Flexible genetic engineering

Moss is haploid by nature and boasts its very own pair of DNA scissors. Engineering its genome is easy. Make any changes you like, wherever you need them: change one nucleotide or a thousand, one site or many. We don’t even need markers to check the correct modifications, just PCR. The moss production system is based on an intact organism, not artificial cell cultures. This guarantees exceptionally reliable and stable modifications.



Pathogen-free processing

The lack of animal pathogens means antibiotics are not necessary. Not only does this ensure constant supply with no threat of contamination. It also eliminates the time and cost-consuming process of removing pathogens in the first place, and ticks another box for regulatory approval.

Integrated fusion toxin production

Moss can produce any desired toxin or toxin fusion protein. Moss cells hardly leak any toxins into the cytosol, but secrete them. Impossible in any other cells!

Talk to us if you would like to develop or improve

- antibodies
- biobetters
- LSD enzymes
- fusion toxins
- virus-like particles/vaccines
- any complex, difficult protein
- efficient and effective glycosylation

Contact

eleva GmbH
Hans-Bunte-Str. 19
79108 Freiburg, Germany

hello@elevabiologics.com
phone +49 761 470 99 0

www.elevabiologics.com